Dishman Pharmaceuticals and Chemicals announced that it holds a license agreement from Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) to produce the active pharmaceutical ingredient (API) of SIRTURO (bedaquiline), a medicine in treatment of Multi-Drug Resistant Tuberculosis (MDR-TB).
Powered by Capital Market - Live News
